New Drug Combo for First-Line Extensive Small Cell Lung Cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests adding a new immunotherapy drug (tarlatamab) to the standard first-line chemo-immunotherapy for extensive-stage small cell lung cancer. It aims to see if the combination works better than the usual treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have extensive-stage small cell lung cancer (cancer that has spread beyond one lung).
- You are 18 years or older.
- You have not had other cancer in the last 2 years (except some skin cancers).
- You do not have active or untreated brain metastases (cancer that has spread to the brain).
- You have not had a heart attack, stroke, or blood clot in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests three experimental drugs (tarlatamab, ZL-1310, and sometimes an immune-boosting drug) together to treat small cell lung cancer. The goal is to see if this combination can slow or shrink the cancer and help you live longer.
This trial tests a new combination of two drugs, tarlatamab and AB248, for people with extensive stage small cell lung cancer that has worsened after at least one prior treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
This trial tests a new combination of drugs (chidamide, a PD-L1 inhibitor, carboplatin, and etoposide) as the first treatment for people with extensive-stage small-cell lung cancer. The goal is to see if this combination works better than standard treatments.
This trial tests a new drug combination (BL-B01D1 plus immunotherapy) as a first treatment for people with advanced small cell lung cancer. It may be an option if you haven't had treatment yet and are healthy enough for chemotherapy.
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.